HotCopper Corporate Spotlight: Interview with Bob Proulx, CEO Imagion Biosystems (ASX:IBX) discussing their medical imaging technology being designated by the FDA as a breakthrough device.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce